Today: 29 June 2026
Browse Category

NASDAQ:MRNA 28 December 2025 - 23 January 2026

Moderna (MRNA) stock jumps after-hours as CEO signals pullback in new vaccine trials

Moderna (MRNA) stock jumps after-hours as CEO signals pullback in new vaccine trials

Moderna shares jumped 4.2% to $51.87 in after-hours trading Thursday after CEO Stephane Bancel said the company will halt new late-stage vaccine trials, citing resistance from U.S. officials and an unreliable U.S. market. The move follows weak COVID vaccine demand and comes as Moderna and Merck reported their experimental cancer vaccine cut melanoma recurrence or death by 49% over five years in a mid-stage study.
23 January 2026
··
Moderna stock jumps again as Merck cancer vaccine data keeps MRNA rally running

Moderna stock jumps again as Merck cancer vaccine data keeps MRNA rally running

Moderna shares rose 7.7% to $53.65 Thursday after five-year data showed its personalized cancer vaccine with Merck’s Keytruda cut melanoma recurrence or death risk by 49%. The phase 2b trial enrolled 157 patients and met its primary endpoint. Investors await phase 3 trial updates and Moderna’s Feb. 13 results call. The stock had jumped 15.8% Wednesday on the initial data release.
22 January 2026
··
Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data

Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data

Moderna shares held steady at $49.81 premarket Thursday after surging 15.8% on five-year melanoma data for its cancer vaccine with Merck. The vaccine-Keytruda combo cut recurrence or death risk by 49% versus Keytruda alone. U.S. vaccine-policy uncertainty is adding risk for the sector. Investors await Moderna’s Feb. 13 earnings call for updates on oncology data and 2026 sales.
22 January 2026
··
Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

Merck shares rose 0.6% to $109.45 Tuesday, defying a broad U.S. market selloff. Five-year data showed its personalized melanoma vaccine with Moderna cut recurrence or death risk by 49% in a Phase 2b trial. Investors await Phase 3 trial timing and Merck’s Feb. 3 earnings call for more details. The S&P 500 fell 2.06% and Nasdaq lost 2.39%.
21 January 2026
·····
Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

Merck shares traded near $108.82 Tuesday after Merck and Moderna reported their personalized melanoma vaccine with Keytruda cut recurrence or death risk by 49% over five years in a phase 2b trial. The stock showed little change following the update. More data will be presented at a future medical meeting. Investors await Merck’s Feb. 3 earnings call for further details on its oncology portfolio.
20 January 2026
····
Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer shares fell 0.6% to $25.42 in late-morning trading Thursday as U.S. vaccine policy changes fueled uncertainty. Sanofi warned of weaker U.S. vaccine demand; Pfizer’s CEO criticized the new recommendations. Moderna and Merck also traded lower. Investors await Pfizer’s Feb. 3 results for updates on 2026 outlook and new product pipeline.
15 January 2026
········
Moderna stock (MRNA) slips in premarket after 17% surge — here’s what investors are watching next

Moderna stock (MRNA) slips in premarket after 17% surge — here’s what investors are watching next

Moderna shares fell about 1% to $39.20 premarket Wednesday after a 17% surge the day before. The company raised its 2025 revenue estimate to $1.9 billion and cut its operating-expense outlook by $200 million. Moderna expects several vaccine approvals and trial updates in 2026, with Q4 results due February 13. U.S. retail vaccination rates dropped 26% in 2025, less than expected.
14 January 2026
·
Moderna stock jumps 12% after $1.9 billion 2025 sales view — what investors watch next

Moderna stock jumps 12% after $1.9 billion 2025 sales view — what investors watch next

Moderna shares jumped 11.7% to $37.81 after the company raised its 2025 sales outlook to about $1.9 billion and cut its operating expense forecast by $200 million. The company reiterated its 2026 growth target and said it does not expect flu or COVID-flu shots to be approved for the 2026 season. Investors await Feb. 13 results and early-2026 cancer vaccine data with Merck.
13 January 2026
··
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 13.01.2026

WHSP Holdings insiders, led by Robert Millner, bought AU$3.4 million in shares over 12 months with no insider sales; insiders now hold 5.4% of the company. JPMorgan Chase dropped over 3% midday after missing estimates, while Moderna surged 14% on a strong 2025 sales forecast. Arch Capital Group trades near $90.77 as momentum slows, with analysts’ targets averaging $108.31. BofA Securities upgraded Coinbase Global to Buy, setting a $340 target.
13 January 2026
·····
Moderna stock slides as $1.9 billion sales view fails to calm investors (MRNA)

Moderna stock slides as $1.9 billion sales view fails to calm investors (MRNA)

Moderna shares fell 4% to $32.92 Monday after the company raised its 2025 revenue forecast to $1.9 billion and projected operating expenses of up to $5.2 billion. CFO Jamey Mock said U.S. retail vaccination rates dropped 26% in 2025. The company expects about $8.1 billion in year-end cash, including $600 million from a new loan. Investors remain cautious as pandemic demand fades and late-stage vaccine trial results approach.
12 January 2026
···
Moderna (MRNA) stock slips after $1.9B 2025 revenue view and cost cuts — what to watch next

Moderna (MRNA) stock slips after $1.9B 2025 revenue view and cost cuts — what to watch next

Moderna shares fell about 2% to $33.60 early Monday after the company forecast $1.9 billion in 2025 revenue and cut its GAAP operating-expense outlook. CFO James Mock said U.S. retail vaccination rates dropped 26% year-on-year, helping sales hit the low end of forecasts. Moderna expects to end 2025 with about $8.1 billion in cash, including a planned $600 million loan draw. CEO Stéphane Bancel announced a $2 billion annual expense cut for 2025.
12 January 2026
·
Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

Bayer’s Monsanto filed a lawsuit against Pfizer, BioNTech, and Moderna in Delaware federal court, alleging misuse of mRNA technology patents. Pfizer shares rose 0.9% to $25.67 in early trading after UBS began coverage with a Neutral rating and a $25 price target. Investors are watching for Pfizer’s Q4 and full-year 2025 results on February 3.
7 January 2026
····
S&P 500 2026 Forecast: 7,490 Target Meets a Data Test as Earnings Season Nears

S&P 500 2026 Forecast: 7,490 Target Meets a Data Test as Earnings Season Nears

The S&P 500 closed at 6,944.82, up 0.62%, while the Dow hit a record. SanDisk surged over 27% and Western Digital gained 17% after Nvidia’s CES appearance. Labor data including JOLTS and payrolls are due this week, with CPI and JPMorgan Chase earnings set for Jan. 13. A Reuters poll shows most strategists expect a 2026 market correction and S&P 500 at 7,490 by year-end.
7 January 2026
·····
Moderna stock slides premarket after 11% surge on flu vaccine filings — what investors watch next

Moderna stock slides premarket after 11% surge on flu vaccine filings — what investors watch next

Moderna shares fell 1.4% to $35.15 premarket Wednesday after a 10.9% surge Tuesday, following news it filed for approval of its mRNA flu vaccine in the U.S., Europe, Canada, and Australia. The company reported 26.6% relative efficacy for the vaccine in adults 50 and older. Bayer’s Monsanto unit sued Moderna and other COVID-19 vaccine makers Tuesday, alleging mRNA patent infringement.
7 January 2026
··
Dow Jones breaks above 49,000 in record close as chip-led rally rolls on

Dow Jones breaks above 49,000 in record close as chip-led rally rolls on

The Dow Jones closed above 49,000 for the first time Tuesday, ending at 49,462.08, up 1%. Chip and healthcare stocks led gains, with Moderna jumping nearly 11% and the PHLX semiconductor index hitting a record. Data-storage shares surged, while Nvidia and AMD slipped after CES presentations. Investors await Wednesday’s JOLTS and Friday’s U.S. jobs report for rate clues.
6 January 2026
······
Dow nears 50,000 as Nvidia CES remarks ignite SanDisk, Micron surge and lift Wall Street

Dow nears 50,000 as Nvidia CES remarks ignite SanDisk, Micron surge and lift Wall Street

The Dow hit a record high Tuesday, rising 1.02% to 49,476.54 as chip and healthcare shares led gains. SanDisk surged 23% on AI hardware optimism tied to CES, while Johnson Controls fell 7.5% after Nvidia’s chip announcement. Investors monitored U.S. jobs data and Fed signals following gaps caused by last year’s federal shutdown.
6 January 2026
············
1 2 3 4

Stock Market Today

  • Soybeans Close Slightly Lower as Traders Reduce Long Positions Ahead of June Acreage Report
    June 28, 2026, 10:43 PM EDT. Soybeans ended Friday's session with minor losses, as July contracts expired and traders adjusted positions ahead of Tuesday's June Acreage report from USDA's National Agricultural Statistics Service (NASS). Speculators trimmed net long soybean positions by 16,139 contracts, mainly through exiting long positions. Cash bean prices declined 2.5 cents to $10.76 per bushel. Soymeal futures fell 40 cents, while soy oil front-month futures gained up to 49 points. Export sales remain strong, with old crop commitments matching USDA projections and new crop sales significantly higher than last year. Market watchers await NASS's report, which is expected to confirm 85.2 million acres planted this spring, potentially impacting prices and trade flows.

Latest articles

Trump-era loan caps could open door for private lenders in grad school market

Trump-era loan caps could open door for private lenders in grad school market

29 June 2026
July 1 federal loan caps slash Grad PLUS access, forcing many graduate and professional students to seek private loans; Sallie Mae projects up to 70% origination growth over several years, while SoFi reports record student-loan volume—investors now face a real-time test of how much demand shifts to private lenders as federal limits hit.
IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

29 June 2026
IREN Limited (NASDAQ:IREN) plunged 21.3% to $47.21 over five straight down days despite announcing a record $50M+ annual Warriors jersey deal, as investors focused on the company’s not fully contracted $4.4B target ARR and high short interest at 19.74% of float, with Friday’s close near the lowest analyst target.
Go toTop